These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28368209)

  • 1. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.
    Gigliotti CL; Ferrara B; Occhipinti S; Boggio E; Barrera G; Pizzimenti S; Giovarelli M; Fantozzi R; Chiocchetti A; Argenziano M; Clemente N; Trotta F; Marchiò C; Annaratone L; Boldorini R; Dianzani U; Cavalli R; Dianzani C
    Drug Deliv; 2017 Nov; 24(1):670-680. PubMed ID: 28368209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer.
    Gigliotti CL; Minelli R; Cavalli R; Occhipinti S; Barrera G; Pizzimenti S; Cappellano G; Boggio E; Conti L; Fantozzi R; Giovarelli M; Trotta F; Dianzani U; Dianzani C
    J Biomed Nanotechnol; 2016 Jan; 12(1):114-27. PubMed ID: 27301177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
    Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R
    Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
    Kim S; Yazici YD; Barber SE; Jasser SA; Mandal M; Bekele BN; Myers JN
    Head Neck; 2006 May; 28(5):389-99. PubMed ID: 16388530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
    Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
    Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
    Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1.
    Pan Z; Fang Q; Li L; Zhang Y; Xu T; Liu Y; Zheng X; Tan Z; Huang P; Ge M
    Cancer Lett; 2021 Mar; 501():31-42. PubMed ID: 33359451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
    Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
    Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
    Gou L; Zou H; Li B
    Cancer Biol Ther; 2019; 20(11):1355-1365. PubMed ID: 31500506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
    Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
    Di Desidero T; Antonelli A; Orlandi P; Ferrari SM; Fioravanti A; Alì G; Fontanini G; Basolo F; Francia G; Bocci G
    Cancer Lett; 2017 Dec; 411():35-43. PubMed ID: 28964784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
    Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
    Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptothecin-Loaded and Manganese Dioxide-Coated Polydopamine Nanomedicine Used for Magnetic Resonance Imaging Diagnosis and Chemo-Photothermal Therapy for Lung Cancer.
    Su M; Chen Y; Jia L; Zhang Z
    Int J Nanomedicine; 2022; 17():6687-6705. PubMed ID: 36597434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.